Athira Pharma downgraded at JMP after Alzheimer’s setback [Seeking Alpha]
Athira Pharma, Inc. (ATHA)
Company Research
Source: Seeking Alpha
Athira Pharma downgraded at JMP after Alzheimerâ??s setbackJun. 23, 2022 2:34 PM ETAthira Pharma, Inc. (ATHA)By:Dulan LokuwithanaSA News Editoraluxum/E+ via Getty ImagesJMP Securities lowered its rating on Athira Pharma (NASDAQ:mild-to-moderate Alzheimerâ??s disease (AD).While the company noted an improvement of certain clinical parameters in a pre-specified subgroup analysis of patients, the JMP analysts led by Jason N. Butler questioned the reproducibility of the effect.Hovering more than 40% below the firmâ??s estimate of cash for the end of 2Q 2022, Athiraâ??s (â??The risk/reward profile for the stock is highly positively skewed should the subgroup findings be replicated in the LIFT-AD trial,â? the analysts added, referring to an ongoing late-stage trial for fosgonimeton in mild-to-moderate Alzheimerâ??s.However, additional visibility is required on plans/timing of LIFT-AD to become more constructive on the stock, according to analysts. â??â?¦.Management has committed to providin
Show less
Read more
Impact Snapshot
Event Time:
ATHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHA alerts
High impacting Athira Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ATHA
News
- Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical OfficerGlobeNewswire
- Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
- Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s DiseaseGlobeNewswire
- Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
ATHA
Earnings
- 11/9/23 - In-Line
ATHA
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 3
- 4/9/24 - Form ARS
- ATHA's page on the SEC website